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Production of murine BCR-ABL fusion protein 
 
B- acute lymphoblastic leukemia (B-ALL) affects adults and children. Treatments with 
tyrosine kinase inhibitors such as Imatinib and Nilotinib are effective at treating patients with 
chronic myeloid leukemia (CML), but are much less effective in patients with B-ALL (Mishra 2006). 
About 25% of adult B-ALL express the BCR-ABL fusion protein due to a chromosomal 
translocation involving human chromosomes 9 and 22 (Rowley 1973). Our preliminary data show 
that numbers of CD4+ T cells specific for BCR-ABL in a naïve mouse are far lower than naïve 
precursor frequencies for other antigen-specific CD4+ T cell populations. Immunizing mice with the 
BCR-ABL antigen and standard adjuvants results in a fifty-fold expansion of BCR-ABL specific T 
cells. However, an effective immune response against BCR-ABL+ acute lymphoblastic leukemia 
will probably require much more dramatic expansion of these antigen-specific T cells. My project 
was to amplify the BCR and ABL genes from Mus musculus and synthesize a BCR-ABL fusion 
protein using those mouse genes.  
We use human BCR-ABL in our mouse experiments and there may be areas of the human 
BCR and ABL fusion protein that are immunogenic to mice but not to humans. Thus, in mice, 
introduction of human BCR-ABL protein potentially elicits an immune response not solely against 
the region spanning the fusion between the two proteins, which is what we are interested in. 
Therefore, I searched the NCBI database for mRNA sequences of BCR (GenBank: BC060270.1) 
and of ABL (NCBI Reference Sequence: NM_001112703.2) in Mus musculus. One result 
appeared for BCR, but there were several mRNA alternative splice variants of c-ABL. 
With this information, I designed primers to amplify mouse BCR and ABL. I also designed 
primers to amplify the truncated proteins to produce the p190 fusion that is associated with B-ALL. 
Literature searches indicated that the first 426 amino acids of BCR are present in P190. The Abl 
portion of P190 is comprised of the kinase, SH2, and SH3 domains of c-ABL (Ren 2005, Ghaffari 
et al 1999). The website Uniprot provided valuable information about the location of the domains; 
this tool helped me to uncover the exact amino acid composition of the P190 fusion. The expected 
lengths of the full-length and truncated forms of BCR and ABL are in the table below: 
Table 1: Length of M. musculus BCR and ABL cDNA 
Full length BCR 2952 nucleotides 
Full length ABL 3429 nucleotides 
Truncated BCR 1279 nucleotides 
Truncated ABL 3249 nucleotides 
I included a three-nucleotide long DNA tail at the 5’ end of the primers to act as a landing pad for 
DNA restriction enzymes. I also included NotI and EcoRI restriction enzyme cut sites and a Kozak 
consensus sequence (ACC) directly upstream of the annealing sequence. To select the restriction 
enzymes, I ensured that there were no restriction enzyme recognition sites for NotI or EcoRI within 
the BCR or ABL sequences, nor in the pMIGR vector, in which BCR-ABL would be inserted, other 
than in the cloning polylinker. 
To obtain template DNA to amplify BCR and ABL, we collected blood from a wild type 
mouse and isolated RNA. Messenger RNA from the total RNA was copied into cDNA, which 
served as template in PCR. During PCR, I encountered problems amplifying the DNA. After 
running 25 cycles of PCR in the thermocycler, there were no distinguishable bands of DNA after 
the gel was visualized, with the exception of primer dimers at the bottom. Even a control reaction 
with a completely different set of primers and template (to rule out that the primers for BCR and 
ABL were just incorrect) resulted in little to no amplification, indicating that the cDNA library was at 
fault. To troubleshoot this, I increased the number of cycles to 35 and used two times the volume 
of template cDNA. This seemed to help: with this approach, I saw bands at around 3kb for 
truncated ABL and a band below 1500 nt, which matched well with the expected band size of 1279 
nt. For full-length ABL, there was a band at 900 nt - this band was excised from the gel for further 
investigation. 
Bands in the gel were cut out and purified by gel extraction. The next step was to add 
adenines onto the blunt ends of the PCR amplicons to facilitate insertion of the amplicons inside a 
pGEM-T-easy plasmid. The TA cloning procedure that we used did not lead to successful 
amplification of pGEM-tr-ABL because we lacked dNTPs. dATPs are required so that Taq 
polymerase can add adenines to the ends of blunt DNA. The lack of this reagent resulted in lower 
transformation efficiencies and could explain why we only obtained empty pGEM-TA vectors from 
analytical restriction digests and sequencing.  
After completing the TA cloning and PCR cleanup, the pGEM-BCR, pGEM-ABL, pGEM-
trBCR (truncated BCR), and pGEM-trABL (truncated ABL) were introduced into DH10B 
Escherichia coli via transformation and the bacteria were plated on LB + carbenicillin (an ampicillin 
analog) + Xgal media; if the gene of interest was inserted into the pGEM vector, it would disrupt 
the lacZ gene and thus colonies would appear white in the presence of the substrate Xgal. I picked 
white colonies and isolated the plasmid DNA via a miniprep procedure. The DNA isolated from the 
bacteria was then digested using restriction enzymes PvuII and HindIII. If the truncated ABL DNA 
had been inserted into the pGEM vector and was digested with PvuII, we would expect to see five 
different bands on a gel. For pGEM-trBCR digested by PvuII, we would expect a total of four 
bands. Because there are no HindIII cut sites in the pGEM vector, nor in the sequence of the 
inserts, we would expect no distinct bands. Results were mixed: for several pGEM-trABL samples, 
I observed bands just below the 3 kb level and at 1.5 kb, which coincide with the expected results, 
but I did not observe any bands at 279 nt or 723 nt. It could be likely that the gel was running for 
too long and that the DNA ran off of the gel; in future experiments, I would let the gel run for a 
shorter period of time, or I would visualize the gel once after ten minutes, and once again after 20 
minutes have passed to ensure that smaller bands are visualized before they disappear from the 
gel. As for the pGEM-trBCR samples, I observed bands corresponding to 2.5 kb and 1 kb. As a 
summary, the expected DNA band sizes for the plasmids when cut with HindIII and PvuII are 
below: 
 
Table 2: Expected band sizes of pGEM-trBCR, pGEM-trABL incubated with PvuII 
pGEM-trBCR digested with PvuII pGEM-trABL digested with PvuII 
2.5 kb 2.5 kb 
1 kb 1.6 kb 
361 nt 957 nt 
279 nt 723 nt 
 279 nt 
 
To increase efficiency of primer binding, I can design a primer with a higher GC percentage or use 
a primer of shorter length (hence a lower Tm). Additionally, having guanine or cytosine at the end 
of the primer will also enhance binding of the primer to the template strand due to those bases 
having three hydrogen bonds as opposed to two. 
 We sent samples of pGEM-trBCR and pGEM-trABL to the University’s Biomedical 
Genomics Center (BMGC) for sequencing to confirm the presence of BCR and ABL in the pGEM 
vector. The sequencing results were not conclusive and did not match the sequence of BCR or 
ABL. I entered some of the sequence into a BLAST search: one sample aligned to c-Abl in M. 
musculus and Rattus norvegicus. For this reason, we continued to work with these samples. I 
changed the TA cloning procedure to increase the efficiency of insertion of our genes of interest 
into the vectors and resubmitted for sequencing in hopes of better results. This is where the 
experiment currently stands at the end of this UROP. We are still attempting to clone BCR and 
ABL and insert the DNA into a plasmid.  
 Once the cloning issues are resolved and we have confirmed that BCR and ABL indeed 
have been inserted into pGEM, we can begin to produce the BCR-ABL fusion peptide. I already 
designed primers for the construction of trBCR-e1a2-trABL and trBCR-2W-trABL. The BCR and 
ABL would be derived from mouse, and DNA encoding an e1a2 peptide from human leukemia 
patients or the 2W1S peptide, which would serve as a control experiment. These amplicons would 
then also be inserted into pGEM, and eventually into a pMIGR retroviral vector containing two long 
terminal repeats (LTRs) that are usually involved in insertion of viral DNA into the host genome. 
The pMIGR vector is used for introducing and expressing target genes into mammalian cells such 
as human or murine hematopoietic cells. Our goal would be to transduce mouse bone marrow cells 
in culture with the pMIGR-trBCR-e1a2-trABL or pMIGR-trBCR-2W1S-trABL. We would then 
examine these cells under a microscope to check for transformation; that is, we would want to 
know if cells expressing murine BCR-ABL have the ability to grow uncontrollably (e.g lack of 
contact inhibition, development of anchorage independence, etc). These cancerous cells would 
then be injected into mice in order to induce leukemia. Our lab is interested in antigen-specific 
CD4+ T cells that can orchestrate an adaptive immune response against these BCR-ABL+ 
leukemic cells. Using flow cytometry, we would quantify and characterize these pivotal cells.  
This type of work was oftentimes tedious and repetitive, but it made me appreciate the 
patience that scientists and researchers must have. It took over three months to insert the genes of 
interest into a bacterial vector because of various problems. With this UROP, I have realized that 
science moves at a glacial pace. However, I am grateful to have had this research experience 
because it challenged me intellectually and tested my ability to problem solve and troubleshoot 
when things did not go as planned. I learned to communicate better and more effectively as well as 
finding the right balance between asking for help when needed and figuring something out on my 
own. I have more trust in my ability to think like a scientist, thanks to UROP, my sponsor Dr. 
Michael Farrar, and my mentor Luke Manlove. 
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